Suite 518, Level 5
165-167 Phillip Street
Sydney NSW Australia 2000

PO Box H100
Australia Square NSW Australia 1215

T +61 2 8098 0819
F +61 2 8080 8315

www.mmjphytotech.com.au
info@mmjphytotech.com.au

ABN 91 601 236 417

ASX RELEASE

24 July 2018

PTL completes Phase 2 clinical trial

MMJ PhytoTech Limited (ASX: MMJ) ("MMJ") is pleased to announce results of the Phase 2 clinical trial ("the trial") undertaken by its wholly-owned subsidiary PhytoTech Therapeutics Ltd ("PTL"). As previously announced, PTL is to be sold by MMJ to Harvest One Cannabis Inc. (TSX-V:HVT), subject to MMJ shareholder approval.

Key elements of the trial

- An open-label, single-centre clinical study to evaluate the safety, tolerability and efficacy of oral administration of the Satipharm CBD capsules as an adjunctive treatment to children suffering from refractory, or treatment-resistant epilepsy
- Comprised of 3 periods: observation (4 weeks), dose-titration and treatment (12 weeks) and follow-up (2 weeks)
- Patients were eligible to participate if they were between 2 and 15 years old, had tried at least four prior anti-epileptic drugs (AEDs), including one trial of a combination of two AEDs, without successful seizure control
- 16 patients were screened and started the CBD treatment. 11 patients completed the study. The mean age of the children participated in the study was 9.1 years (SD: 3.40 years). The mean dose in maintenance was 13.6 mg/kg (SD: 4.24 mg/kg). Patient adherence to treatment was very high (mean of 96%)

Key findings of the trial

- Promising evidences of efficacy were demonstrated
- Satipharm's CBD capsules significantly reduced monthly seizure frequency in the treatment-resistant children when added to current medications. The median reduction was -82% in the 12-week treatment period compared to the 4-week observation period
- 9/16 patients (56%) who started the treatment had a reduction of at least 50% in total number of seizures during the entire treatment period, compared to observation
- Following 12 weeks of treatment, 8/11 patients (73%) were rated as "very much improved/improved" in overall condition on the Caregiver Global Impression of Improvement scale and 9/11 patients (82%) were rated as "very much reduced/reduced" on that scale
- Prof. Uri Kramer, Director of Pediatric Epilepsy Service, Tel Aviv Sourasky Medical Center and Principal Investigator of the trial commented that "Notwithstanding the small number of patients treated, the efficacy of Satipharm's CBD capsules as add-on therapy in the treatment of pediatric, intractable epilepsy has been shown. Moreover, these results compare favourably to other similar studies of cannabidiol, including those published by GW Pharmaceuticals. Importantly, the significant reductions in seizure frequency while demonstrating satisfactory safety and tolerability profile, in these very difficult to treat patients, have the potential to be a life-altering event for these patients and their families. I would be greatly interested in prescribing such standardized and clinically tested product as Satipharm's CBD"

Suite 518, Level 5
165-167 Phillip Street
Sydney NSW Australia 2000

PO Box H100
Australia Square NSW Australia 1215

T +61 2 8098 0819
F +61 2 8080 8315

www.mmjphytotech.com.au
info@mmjphytotech.com.au

ABN 91 601 236 417

ASX RELEASE

- - - - - - - - - -

Investor and Media Enquiries
Jason Conroy
Chief Executive Officer
T +61 2 8098 0819
jconroy@mmjphytotech.com.au

About MMJ
MMJ is a global cannabis investment company. MMJ owns a portfolio of minority investments and aims to invest across the full range of emerging cannabis-related sectors including healthcare, technology, infrastructure, logistics, processing, cultivation, equipment and retail. For MMJ's latest investor presentation and news, please visit: https://www.mmjphytotech.com.au/investors/

Important Notice
This announcement contains reference to certain intentions, expectations, future plans, strategy and prospects of MMJ. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of MMJ may be influenced by a number of factors, many of which are outside the control of MMJ. No representation or warranty, express or implied, is made by MMJ, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause MMJ's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. MMJ does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in MMJ. This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any "US person" as defined in Regulation S under the US Securities Act of 1993 ("Securities Act"). MMJ's shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.